224 related articles for article (PubMed ID: 25868510)
1. The position of strontium ranelate in today's management of osteoporosis.
Reginster JY; Brandi ML; Cannata-Andía J; Cooper C; Cortet B; Feron JM; Genant H; Palacios S; Ringe JD; Rizzoli R
Osteoporos Int; 2015 Jun; 26(6):1667-71. PubMed ID: 25868510
[TBL] [Abstract][Full Text] [Related]
2. Cardiac concerns associated with strontium ranelate.
Reginster JY
Expert Opin Drug Saf; 2014 Sep; 13(9):1209-13. PubMed ID: 25020233
[TBL] [Abstract][Full Text] [Related]
3. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate.
Abrahamsen B; Grove EL; Vestergaard P
Osteoporos Int; 2014 Feb; 25(2):757-62. PubMed ID: 24322475
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
[TBL] [Abstract][Full Text] [Related]
6. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
Hiligsmann M; Vanoverberghe M; Neuprez A; Bruyère O; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):359-66. PubMed ID: 20715911
[TBL] [Abstract][Full Text] [Related]
8. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.
Cooper C; Fox KM; Borer JS
Osteoporos Int; 2014 Feb; 25(2):737-45. PubMed ID: 24322476
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.
Hiligsmann M; Ben Sedrine W; Bruyère O; Reginster JY
Osteoporos Int; 2013 Aug; 24(8):2291-300. PubMed ID: 23371359
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.
Borgström F; Ström O; Coelho J; Johansson H; Oden A; McCloskey E; Kanis JA
Osteoporos Int; 2010 Feb; 21(2):339-49. PubMed ID: 19513577
[TBL] [Abstract][Full Text] [Related]
11. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
Adami S
Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Inderjeeth CA; Foo AC; Lai MM; Glendenning P
Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
[TBL] [Abstract][Full Text] [Related]
13. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
Osborne V; Layton D; Perrio M; Wilton L; Shakir SA
Drug Saf; 2010 Jul; 33(7):579-91. PubMed ID: 20553059
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
Stevenson M; Davis S; Lloyd-Jones M; Beverley C
Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
Kanis JA; Johansson H; Oden A; McCloskey EV
Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
[TBL] [Abstract][Full Text] [Related]
16. Strontium ranelate: a look back at its use for osteoporosis.
Reginster JY; Neuprez A
Expert Opin Pharmacother; 2010 Dec; 11(17):2915-27. PubMed ID: 21050035
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on strontium ranelate: in postmenopausal osteoporosis.
Deeks ED; Dhillon S
Drugs Aging; 2010 Sep; 27(9):771-3. PubMed ID: 20809666
[TBL] [Abstract][Full Text] [Related]
18. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
Ortolani S; Vai S
Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319
[TBL] [Abstract][Full Text] [Related]
19. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
[TBL] [Abstract][Full Text] [Related]
20. Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis.
Deeks ED; Dhillon S
Drugs; 2010 Apr; 70(6):733-59. PubMed ID: 20394457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
